EUVIMEDEUVIMED entdecken
KorrekturOpen Access

Correction to “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”

International Forum of Allergy & Rhinology · 2026-06 · 16 (6) · 654-655

DOI: 10.1002/alr.70172 ↗

Kurz gefasst

Korrektur in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 11.05.2026. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Correction to “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”. International Forum of Allergy & Rhinology, 16(6), 654-655. https://doi.org/10.1002/alr.70172

Vancouver

Correction to “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”. International Forum of Allergy & Rhinology. 2026;16(6):654-655. doi:10.1002/alr.70172

BibTeX
@article{euvimed2026,
  title = {Correction to “Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes”},
  journal = {International Forum of Allergy & Rhinology},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {654--655},
  doi = {10.1002/alr.70172}
}
Kostenlos starten →